Correction: Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis

Figs 2, 3, and 4 are incorrect. The figures contain information that does not correspond to the results presented in the article. The authors have provided corrected versions here.

Fig 2. Relative fold change (relative to untreated control cells) of the EGFR gene among LS174T and IEC-18 cells.

Results were expressed as mean; error bars (SD); n = 3. Statistical analysis was performed using one-way ANOVA test. * indicates P-values less than 0.05, ** indicates P-values less than 0.01, and *** indicates P-values less than 0.001. Untreated cells were used as negative controls and cetuximab and trastuzumab were used as positive controls.

Fig 3. Relative fold change (relative to untreated control cells) of the HER-2 gene among LS174T and IEC-18 cells.

Results were expressed as mean; error bars (SD); n = 3. Statistical analysis was performed using one-way ANOVA test. * indicates P-values less than 0.05, ** indicates P-values less than 0.01, and *** indicates P-values less than 0.001. Untreated cells were used as negative controls and cetuximab and trastuzumab were used as positive controls.

Fig 4. Relative fold change (relative to untreated control cells) of the PTGS-2 gene among LS174T and IEC-18 cells.

Results were expressed as mean; error bars (SD); n = 3. Statistical analysis was performed using one-way ANOVA test. * indicates P-values less than 0.05, ** indicates P-values less than 0.01, and *** indicates P-values less than 0.001. Untreated cells were used as negative controls and cetuximab and trastuzumab were used as positive controls.